Fol. Biol. 2020, 66, 117-122

https://doi.org/10.14712/fb2020066040117

PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population

J. Karolova1,2, M. Radek1,3, K. Helman4, M. Spacek1,3, Marek Trněný1, Pavel Klener1,2

11st Department of Medicine, Department of Haematology, Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
2Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
3Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
4Faculty of Informatics and Statistics, University of Economics, Prague, Czech Republic

Received September 2020
Accepted November 2020

Crossref Cited-by Linking

  • Su Manqi, Zhang Zhanna, Jiang Panruo, Wang Xiaoxia, Tong Xiangmin, Wu Gongqiang: CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies. Cell Transplant 2024, 33. <https://doi.org/10.1177/09636897241293964>
  • Lokhande Lavanya, Nilsson Daniel, de Matos Rodrigues Joana, Hassan May, Olsson Lina M., Pyl Paul-Theodor, Vasquez Louella, Porwit Anna, Gerdtsson Anna Sandström, Jerkeman Mats, Ek Sara: Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients. Cancers 2024, 16, 2289. <https://doi.org/10.3390/cancers16132289>
  • Xiong Jian, Yang Jie, Sun Yuling, Chen Yachun, Guo Yundi, Liu Cuiping, Sun Jing: Dysregulated PD-L2 is correlated with disease activity and inflammation in rheumatoid arthritis. Immunogenetics 2023, 75, 425. <https://doi.org/10.1007/s00251-023-01307-7>
  • Ameli Fereshteh, Shajareh Elham, Mokhtari Maral, Kosari Farid: Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma. BMC Cancer 2022, 22. <https://doi.org/10.1186/s12885-022-09803-x>
  • Zhao Wanying, Liang Yuanzheng, Wang Liang: Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. APT 2021, 3, 84. <https://doi.org/10.31491/APT.2021.12.071>
Crossref Cited-by Linking logo